Syne Qua Non Limited   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Diss United Kingdom (1996)

Organization Overview

First Clinical Trial
2015
NCT02578940
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Syne Qua Non Limited

Active Ingredients

Drugs in Phase 3 Trials (1)

Fluciclovine (Axumin) (2 trials)

Drugs in Phase 2 Trials (3)

aav2/5 optirpe65 (1 trial)

aav-rpgr (1 trial)

raav.hcnga3 (1 trial)

Drugs in Phase 1 Trials (1)

azathioprine (imuran) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Color Vision Defects (Phase 2)

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 5